These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 20081592)

  • 1. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
    Sprakes MB; Hamlin PJ
    Br J Hosp Med (Lond); 2009 Nov; 70(11):644-7. PubMed ID: 20081592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Closing fistulas in Crohn's disease--should the accent be on maintenance or safety?
    Fiocchi C
    N Engl J Med; 2004 Feb; 350(9):934-6. PubMed ID: 14985492
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adalimumab in infliximab refractory Crohn's disease -- the next generation of anti-TNF-alpha-therapy?].
    Heidemann J; Kucharzik T
    Z Gastroenterol; 2005 Jul; 43(7):689-90. PubMed ID: 16001352
    [No Abstract]   [Full Text] [Related]  

  • 4. How to manage difficult Crohn's disease: optimum delivery of anti-TNFs.
    Krygier DS; Ko HH; Bressler B
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):407-15. PubMed ID: 19673627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience.
    Danese S; Colombel JF; Reinisch W; Rutgeerts PJ
    Aliment Pharmacol Ther; 2011 Apr; 33(8):857-69. PubMed ID: 21320139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Certolizumab (Cimzia) for Crohn's disease.
    Med Lett Drugs Ther; 2008 Oct; 50(1297):81-2. PubMed ID: 18927521
    [No Abstract]   [Full Text] [Related]  

  • 7. Education and imaging. Gastrointestinal: Improvement of granuloma annulare with anti-tumour necrosis factor alpha therapy for Crohn's disease.
    Fanning SB; Chapman G; Yau Y; Leong RW
    J Gastroenterol Hepatol; 2010 Jan; 25(1):215. PubMed ID: 20136975
    [No Abstract]   [Full Text] [Related]  

  • 8. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 9. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytomegalovirus primary infection in a patient with Crohn's disease treated with azathioprine and anti-TNF alpha].
    Ben Hriz F; Habbessi H; Maamouri N; Belkahla N; Ouerdiane S; Chouaib S; Ouerghi H; Chaabouni H; Ben Mami N
    Tunis Med; 2009 Aug; 87(8):545-6. PubMed ID: 20180364
    [No Abstract]   [Full Text] [Related]  

  • 11. Balancing the risks and benefits of prolonged use of infliximab.
    Schölmerich J
    Gut; 2009 Apr; 58(4):477-8. PubMed ID: 19299379
    [No Abstract]   [Full Text] [Related]  

  • 12. TNF-alpha antagonists for the treatment of Crohn's disease.
    Kam LY; Targan SR
    Expert Opin Pharmacother; 2000 May; 1(4):615-22. PubMed ID: 11249506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing complicated Crohn's disease in children and adolescents.
    Homan M; Baldassano RN; Mamula P
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for Crohn's disease.
    Matsuoka K; Kanai T
    Digestion; 2013; 88(1):17-9. PubMed ID: 23797247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-TNF (infliximab) treatment in Crohn disease: safety profile].
    Carroccio A; Di Prima L; Pirrone G; Ambrosiano G; Noto D; Cefalù AB
    Recenti Prog Med; 2006 Feb; 97(2):108-12; quiz 122. PubMed ID: 16671277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.